請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72238
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳俊任(Chun-Jen Chen) | |
dc.contributor.author | Ching-Han Lin | en |
dc.contributor.author | 林敬涵 | zh_TW |
dc.date.accessioned | 2021-06-17T06:30:39Z | - |
dc.date.available | 2022-09-14 | |
dc.date.copyright | 2020-09-29 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-09-17 | |
dc.identifier.citation | 1. Chang TT, Chen T. Ganoderma formosanum Sp-Nov on Formosan Sweet Gum in Taiwan. Transactions of the British Mycological Society. 1984:731-3. 2. Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnology Annual Review. 2007. p. 265-301. 3. Ahmad MF. Ganoderma lucidum: Persuasive biologically active constituents and their health endorsement. Biomed Pharmacother. 2018; 107:507-19. 4. Cör D, Knez Ž, Knez Hrnčič M. Antitumour, Antimicrobial, Antioxidant and Antiacetylcholinesterase Effect of Ganoderma Lucidum Terpenoids and Polysaccharides: A Review. Molecules. 2018; 23(3). 5. Li J, Gu F, Cai C, Hu M, Fan L, Hao J, et al. Purification, structural characterization, and immunomodulatory activity of the polysaccharides from Ganoderma lucidum. Int J Biol Macromol. 2020; 143:806-13. 6. Lu J, He R, Sun P, Zhang F, Linhardt RJ, Zhang A. Molecular mechanisms of bioactive polysaccharides from Ganoderma lucidum (Lingzhi), a review. Int J Biol Macromol. 2020; 150:765-74. 7. Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2016; 4:CD007731. 8. Wang C, Liu X, Lian C, Ke J, Liu J. Triterpenes and Aromatic Meroterpenoids with Antioxidant Activity and Neuroprotective Effects from Ganoderma lucidum. Molecules. 2019; 24(23). 9. Su HG, Peng XR, Shi QQ, Huang YJ, Zhou L, Qiu MH. Lanostane triterpenoids with anti-inflammatory activities from Ganoderma lucidum. Phytochemistry. 2020; 173:112256. 10. Lu SY, Shi QQ, Peng XR, Zhou L, Li XN, Qiu MH. Isolation of benzolactones, Ganodumones A-F from Ganoderma lucidum and their antibacterial activities. Bioorg Chem. 2020; 98:103723. 11. Rašeta M, Popović M, Čapo I, Stilinović N, Vukmirović S, Milošević B, et al. Antidiabetic effect of two different Ganoderma species tested in alloxan diabetic rats. RSC Advances. 2020; 10(17):10382-93. 12. Zeng P, Guo Z, Zeng X, Hao C, Zhang Y, Zhang M, et al. Chemical, biochemical, preclinical and clinical studies of Ganoderma lucidum polysaccharide as an approved drug for treating myopathy and other diseases in China. J Cell Mol Med. 2018; 22(7):3278-97. 13. Sasaki T, Arai Y, Ikekawa T, Chihara G, Fukuoka F. Antitumor polysaccharides from some polyporaceae, Ganoderma applanatum (Pers.) Pat and Phellinus linteus (Berk. et Curt) Aoshima. Chem Pharm Bull (Tokyo). 1971; 19(4):821-6. 14. Ferreira IC, Heleno SA, Reis FS, Stojkovic D, Queiroz MJ, Vasconcelos MH, et al. Chemical features of Ganoderma polysaccharides with antioxidant, antitumor and antimicrobial activities. Phytochemistry. 2015; 114:38-55. 15. Jiang Y, Chang Y, Liu Y, Zhang M, Luo H, Hao C, et al. Overview of Ganoderma sinense polysaccharide-an adjunctive drug used during concurrent Chemo/Radiation therapy for cancer treatment in China. Biomed Pharmacother. 2017; 96:865-70. 16. Kong M, Yao Y, Zhang H. Antitumor activity of enzymatically hydrolyzed Ganoderma lucidum polysaccharide on U14 cervical carcinoma-bearing mice. Int J Immunopathol Pharmacol. 2019; 33:2058738419869489. 17. Zheng Y, Bai L, Zhou YP, Tong RS, Zeng MH, Li XF, et al. Polysaccharides from Chinese herbal medicine for anti-diabetes recent advances. Int J Biol Macromol. 2019; 121:1240-53. 18. Zheng Y, Li L, Cai T. Cordyceps polysaccharide ameliorates airway inflammation in an ovalbumin-induced mouse model of asthma via TGF-beta1/Smad signaling pathway. Respir Physiol Neurobiol. 2020; 276:103412. 19. Hu F, Yan Y, Wang CW, Liu Y, Wang JJ, Zhou F, et al. Article Effect and Mechanism of Ganoderma lucidum Polysaccharides on Human Fibroblasts and Skin Wound Healing in Mice. Chin J Integr Med. 2019; 25(3):203-9. 20. Hu S, Huang J, Pei S, Ouyang Y, Ding Y, Jiang L, et al. Ganoderma lucidum polysaccharide inhibits UVB-induced melanogenesis by antagonizing cAMP/PKA and ROS/MAPK signaling pathways. J Cell Physiol. 2019; 234(5):7330-40. 21. Li L, Fu WW, Wu RT, Song YH, Wu WY, Yin SH, et al. Protective effect of Ganoderma atrum polysaccharides in acute lung injury rats and its metabolomics. Int J Biol Macromol. 2020; 142:693-704. 22. Wang CL, Lu CY, Pi CC, Zhuang YJ, Chu CL, Liu WH, et al. Extracellular polysaccharides produced by Ganoderma formosanum stimulate macrophage activation via multiple pattern-recognition receptors. BMC Complement Altern Med. 2012; 12:119. 23. Wang CL, Pi CC, Kuo CW, Zhuang YJ, Khoo KH, Liu WH, et al. Polysaccharides purified from the submerged culture of Ganoderma formosanum stimulate macrophage activation and protect mice against Listeria monocytogenes infection. Biotechnol Lett. 2011; 33(11):2271-8. 24. Pi CC, Chu CL, Lu CY, Zhuang YJ, Wang CL, Yu YH, et al. Polysaccharides from Ganoderma formosanum function as a Th1 adjuvant and stimulate cytotoxic T cell response in vivo. Vaccine. 2014; 32 (3):401-8. 25. Pi CC, Wang HY, Lu CY, Lu FL, Chen CJ. Ganoderma formosanum polysaccharides attenuate Th2 inflammation and airway hyperresponsiveness in a murine model of allergic asthma. Springerplus. 2014; 3:297. 26. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019; 129(4):1493-503. 27. Lambrecht BN, Hammad H, Fahy JV. The Cytokines of Asthma. Immunity. 2019; 50(4):975-91. 28. Akdis CA, Arkwright PD, Bruggen MC, Busse W, Gadina M, Guttman-Yassky E, et al. Type 2 immunity in the skin and lungs. Allergy. 2020. 29. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008; 454(7203):445-54. 30. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. The Lancet. 2018; 391(10122):783-800. 31. Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015; 135(3):626-35. 32. Hirahara K, Nakayama T. CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int Immunol. 2016; 28(4):163-71. 33. Spellberg B, Edwards JE, Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis. 2001; 32(1):76-102. 34. Lloyd CM, Snelgrove RJ. Type 2 immunity: Expanding our view. Sci Immunol. 2018; 3(25). 35. Gause WC, Rothlin C, Loke P. Heterogeneity in the initiation, development and function of type 2 immunity. Nat Rev Immunol. 2020. 36. Gurram RK, Zhu J. Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses. Cell Mol Immunol. 2019; 16(3):225-35. 37. Pivniouk V, Gimenes Junior JA, Honeker LK, Vercelli D. The role of innate immunity in asthma development and protection: Lessons from the environment. Clin Exp Allergy. 2020; 50(3):282-90. 38. He SH, Zhang HY, Zeng XN, Chen D, Yang PC. Mast cells and basophils are essential for allergies: mechanisms of allergic inflammation and a proposed procedure for diagnosis. Acta Pharmacol Sin. 2013; 34(10):1270-83. 39. Mendez-Enriquez E, Hallgren J. Mast Cells and Their Progenitors in Allergic Asthma. Front Immunol. 2019; 10:821. 40. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010; 125(2 Suppl 2):S73-80. 41. Bakakos A, Loukides S, Bakakos P. Severe Eosinophilic Asthma. J Clin Med. 2019; 8(9). 42. Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res. 2018; 19(1):113. 43. George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016; 7(1):34-51. 44. Pascal M, Perez-Gordo M, Caballero T, Escribese MM, Lopez Longo MN, Luengo O, et al. Microbiome and Allergic Diseases. Front Immunol. 2018; 9:1584. 45. Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe. 2011; 10(4):311-23. 46. Palm NW, de Zoete MR, Flavell RA. Immune-microbiota interactions in health and disease. Clin Immunol. 2015; 159(2):122-7. 47. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. 2014; 20(2):159-66. 48. Lynch SV. Gut Microbiota and Allergic Disease. New Insights. Ann Am Thorac Soc. 2016; 13 Suppl 1:S51-4. 49. Xu X, Xu P, Ma C, Tang J, Zhang X. Gut microbiota, host health, and polysaccharides. Biotechnol Adv. 2013; 31(2):318-37. 50. Li LF, Liu HB, Zhang QW, Li ZP, Wong TL, Fung HY, et al. Comprehensive comparison of polysaccharides from Ganoderma lucidum and G. sinense: chemical, antitumor, immunomodulating and gut-microbiota modulatory properties. Sci Rep. 2018; 8(1):6172. 51. Chang CJ, Lin CS, Lu CC, Martel J, Ko YF, Ojcius DM, et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. 2015; 6:7489. 52. Li K, Zhuo C, Teng C, Yu S, Wang X, Hu Y, et al. Effects of Ganoderma lucidum polysaccharides on chronic pancreatitis and intestinal microbiota in mice. Int J Biol Macromol. 2016; 93(Pt A):904-12. 53. Jin M, Zhu Y, Shao D, Zhao K, Xu C, Li Q, et al. Effects of polysaccharide from mycelia of Ganoderma lucidum on intestinal barrier functions of rats. Int J Biol Macromol. 2017; 94(Pt A):1-9. 54. Barcik W, Boutin RCT, Sokolowska M, Finlay BB. The Role of Lung and Gut Microbiota in the Pathology of Asthma. Immunity. 2020; 52(2):241-55. 55. Abrahamsson TR, Wu RY, Jenmalm MC. Gut microbiota and allergy: the importance of the pregnancy period. Pediatr Res. 2015;77(1-2):214-9. 56. Muir AB, Benitez AJ, Dods K, Spergel JM, Fillon SA. Microbiome and its impact on gastrointestinal atopy. Allergy. 2016; 71(9):1256-63. 57. Arrieta M-C, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Science Translational Medicine. 2015; 7(307):307ra152-307ra152. 58. Hufnagl K, Pali-Scholl I, Roth-Walter F, Jensen-Jarolim E. Dysbiosis of the gut and lung microbiome has a role in asthma. Semin Immunopathol. 2020; 42(1):75-93. 59. World Health Organization. Asthma Geneva: World Health Organization; 2020 60. Ministry of Health and Welfare (Taiwan). 2013 年國民健康訪問調查結果報告. Taiwan; 2013. 61. Melgert BN, Postma DS, Kuipers I, Geerlings M, Luinge MA, van der Strate BW, et al. Female mice are more susceptible to the development of allergic airway inflammation than male mice. Clin Exp Allergy. 2005; 35(11):1496-503. 62. Amplicon P, Clean‐Up P, Index P. 16s metagenomic sequencing library preparation. 63. Hu G, Christman JW. Editorial: Alveolar Macrophages in Lung Inflammation and Resolution. Frontiers in Immunology. 2019; 10(2275). 64. Dillon SM, Kibbie J, Lee EJ, Guo K, Santiago ML, Austin GL, et al. Low abundance of colonic butyrate-producing bacteria in HIV infection is associated with microbial translocation and immune activation. Aids. 2017; 31(4):511-21. 65. La Rosa SL, Leth ML, Michalak L, Hansen ME, Pudlo NA, Glowacki R, et al. The human gut Firmicute Roseburia intestinalis is a primary degrader of dietary beta-mannans. Nat Commun. 2019; 10(1):905. 66. Sánchez E, Ribes-Koninckx C, Calabuig M, Sanz Y. Intestinal Staphylococcus spp. and virulent features associated with coeliac disease. Journal of Clinical Pathology. 2012; 65(9):830-4. 67. Fazlollahi M, Chun Y, Grishin A, Wood RA, Burks AW, Dawson P, et al. Early-life gut microbiome and egg allergy. Allergy. 2018; 73(7):1515-24. 68. Naito Y, Uchiyama K, Takagi T. A next-generation beneficial microbe: Akkermansia muciniphila. J Clin Biochem Nutr. 2018; 63(1):33-5. 69. Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature medicine. 2019; 25(7):1096-103. 70. McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019; 199(4):433-45. 71. Ding Z, Wang Q, Peng L, Zhang L, Gu Z, Shi G, et al. Relationship between mycelium morphology and extracellular polysaccharide production of medicinal mushroom Ganoderma lucidum in submerged culture. Journal of Medicinal Plants Research. 2012; 6(14):2868-74. 72. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 1987; 236(4804):944-7. 73. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov. 2013; 12(2):117-29. 74. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 2002; 8(8):885-9. 75. Zhang Q, Lai K, Xie J, Chen G, Zhong N. Does unrestrained single-chamber plethysmography provide a valid assessment of airway responsiveness in allergic BALB/c mice? Respir Res. 2009; 10:61. 76. Tang C, Ding R, Sun J, Liu J, Kan J, Jin C. The impacts of natural polysaccharides on intestinal microbiota and immune responses – a review. Food Function. 2019; 10(5):2290-312. 77. Hu S, Wang J, Xu Y, Yang H, Wang J, Xue C, et al. Anti-inflammation effects of fucosylated chondroitin sulphate from Acaudina molpadioides by altering gut microbiota in obese mice. Food Function. 2019; 10(3):1736-46. 78. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett. 2002; 217(2):133-9. 79. Pajak B, Orzechowski A, Gajkowska B. Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells. Adv Med Sci. 2007; 52: 83-8. 80. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008; 27(2):104-19. 81. Barcik W, Pugin B, Brescó MS, Westermann P, Rinaldi A, Groeger D, et al. Bacterial secretion of histamine within the gut influences immune responses within the lung. Allergy. 2019; 74(5):899-909. 82. Van Gylswyk NO, Van Der Toorn JJTK. Eubacterium uniforme sp. nov. and Eubacterium xylanophilum sp. nov., Fiber-Digesting Bacteria from the Rumina of Sheep Fed Corn Stover. International Journal of Systematic and Evolutionary Microbiology. 1985; 35(3):323-6. 83. Freier TA, Beitz DC, Li L, Hartman PA. Characterization of Eubacterium coprostanoligenes sp. nov., a cholesterol-reducing anaerobe. Int J Syst Bacteriol. 1994; 44(1):137-42. 84. Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, et al. Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. Oncol Rep. 2016; 35(1):325-33. 85. He J, Guo H, Zheng W, Xue Y, Zhao R, Yao W. Heat stress affects fecal microbial and metabolic alterations of primiparous sows during late gestation. J Anim Sci Biotechnol. 2019; 10:84. 86. Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. New England Journal of Medicine. 2013; 368(5):407-15. 87. Juul FE, Garborg K, Bretthauer M, Skudal H, Øines MN, Wiig H, et al. Fecal Microbiota Transplantation for Primary Clostridium difficile Infection. New England Journal of Medicine. 2018; 378(26):2535-6. 88. Hu S, Xu Y, Gao X, Li S, Jiang W, Liu Y, et al. Long-Chain Bases from Sea Cucumber Alleviate Obesity by Modulating Gut Microbiota. Mar Drugs. 2019; 17(8). 89. Wang YN, Meng XC, Dong YF, Zhao XH, Qian JM, Wang HY, et al. Effects of probiotics and prebiotics on intestinal microbiota in mice with acute colitis based on 16S rRNA gene sequencing. Chin Med J (Engl). 2019; 132(15):1833-42. 90. Coffey MJ, Nielsen S, Wemheuer B, Kaakoush NO, Garg M, Needham B, et al. Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis. Sci Rep. 2019; 9(1):18593. 91. Han K, Jin W, Mao Z, Dong S, Zhang Q, Yang Y, et al. Microbiome and butyrate production are altered in the gut of rats fed a glycated fish protein diet. Journal of Functional Foods. 2018; 47:423-33. 92. Chen YH, Bai J, Wu D, Yu SF, Qiang XL, Bai H, et al. Association between fecal microbiota and generalized anxiety disorder: Severity and early treatment response. J Affect Disord. 2019; 259:56-66. 93. Berni Canani R, Sangwan N, Stefka AT, Nocerino R, Paparo L, Aitoro R, et al. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants. ISME J. 2016; 10(3):742-50. 94. Li H, Liu F, Lu J, Shi J, Guan J, Yan F, et al. Probiotic Mixture of Lactobacillus plantarum Strains Improves Lipid Metabolism and Gut Microbiota Structure in High Fat Diet-Fed Mice. Frontiers in microbiology. 2020; 11:[512 p.]. 95. Guo M, Li Z. Polysaccharides isolated from Nostoc commune Vaucher inhibit colitis-associated colon tumorigenesis in mice and modulate gut microbiota. Food Funct. 2019; 10(10):6873-81. 96. Wang Z, Wang Q, Zhao J, Gong L, Zhang Y, Wang X, et al. Altered diversity and composition of the gut microbiome in patients with cervical cancer. AMB Express. 2019; 9(1):40. 97. Oliveira A, Oliveira LC, Aburjaile F, Benevides L, Tiwari S, Jamal SB, et al. Insight of Genus Corynebacterium: Ascertaining the Role of Pathogenic and Non-pathogenic Species. Frontiers in Microbiology. 2017; 8(1937). 98. Misharin AV, Morales-Nebreda L, Mutlu GM, Budinger GR, Perlman H. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am J Respir Cell Mol Biol. 2013; 49(4):503-10. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72238 | - |
dc.description.abstract | 台灣紫芝 (Ganoderma formosanum) 為台灣靈芝屬之特有品種,本實驗室透過液態深層發酵培養法生產靈芝胞外多醣體,並經膠體過濾法純化出PS-F2。在先前研究中發現,利用腹腔注射的方式給予PS-F2能夠減少過敏型氣喘所造成之呼吸道阻力並降低肺部發炎反應;本研究主要探討,連續口服PS-F2是否也能夠降低過敏型氣喘的症狀並減少肺部發炎反應。在本動物模型中重複以OVA和鋁鹽誘導免疫作用並以OVA自鼻腔刺激誘導過敏型氣喘。研究結果顯示,口服低劑量 (125 mg/kg) PS-F2能夠減輕小鼠過敏型氣喘所造成之呼吸道阻力並且有效降低具OVA抗原專一性抗體IgG1以及IgG2a在血清中之含量,但無法降低肺部發炎反應。口服高劑量 (250 mg/kg) PS-F2未能減輕小鼠過敏型氣喘所造成之呼吸道阻力,亦無法下調具有OVA專一性抗體IgE、IgG1以及IgG2a的產生;然而,浸潤至肺部當中的嗜酸性球與第二型免疫反應相關細胞激素的產生有下調的情形。本研究另一部分探討,腸道微生物是否利用PS-F2改變腸道中菌相之組成,以及腸道菌相是否在過敏型氣喘小鼠中與PS-F2之免疫調節作用有關。分析小鼠糞便中所抽取之16S rDNA發現,誘導過敏型氣喘發生後,降低小鼠腸道菌相之α多樣性,但攝取PS-F2並無法改變α多樣性;過敏型氣喘明顯改變小鼠腸道菌相之β多樣性,而攝取PS-F2無法進一步改變β多樣性。綜合來說,攝取PS-F2無法明顯改變過敏型氣喘小鼠之腸道菌相,而攝取PS-F2是否影響過敏型氣喘仍需要進一步驗證。 | zh_TW |
dc.description.abstract | Ganoderma formosanum is the endemic species of Ganoderma isolated in Taiwan. We produced extracellular polysaccharides of G. formosanum by submerged culture and purified the second fraction of polysaccharides (PS-F2) by gel filtration. In the previous study, we found that PS-F2 treatment by intraperitoneal injection could alleviate the symptom of allergic asthma and downregulate the inflammation in the lung. In this study, we investigated whether continuous PS-F2 treatment by oral gavage could also alleviate chicken ovalbumin (OVA)-induced allergic asthma and downregulate lung inflammation in mice. In this model, mice were sensitized by repeated immunization with OVA and alum, followed by intranasal challenge of OVA to induced acute asthma. The results showed that PS-F2 treatment at a lower dose (125 mg/kg) could alleviate airway hyperresponsiveness (AHR) and decrease serum levels of OVA-specific IgG1 and IgG2a, although pulmonary inflammation was not affected. PS-F2 treatment at a higher dose (250 mg/kg) did not affect AHR and serum levels of OVA-specific IgE, IgG1 and IgG2a; however, eosinophil infiltration in the lung and the production of type 2 immunity-associated cytokine were downregulated. In this study, we also explored whether the composition of gut microbiota was altered by PS-F2 administration, and whether it was associated with the immunomodulatory effect of PS-F2 in mice with allergic asthma. By analyzing fecal 16s rDNA, we found that the α diversity of gut microbiota was reduced in OVA-immunized mice, but PS-F2 treatment did not change the α diversity of gut microbiota. OVA immunization significantly changed the β diversity of gut microbiota, which was not further altered by PS-F2 treatment. Taken together, PS-F2 treatment did not significantly alter the composition of gut microbiota, and whether PS-F2 administration affects allergic asthma will require further validation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:30:39Z (GMT). No. of bitstreams: 1 U0001-1609202012081000.pdf: 6326850 bytes, checksum: 86b141ff3e2facaf262cade87d4946d6 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 論文口試委員審定書 I 誌謝 II 中文摘要 III Abstract IV 縮寫表 VI 目錄 VIII 圖目錄 XI 第一章 緒論 1 一、靈芝 1 二、靈芝多醣體 2 三、過敏型氣喘 3 四、第二型免疫反應 4 1. 肥大細胞與嗜鹼性球 5 2. 嗜酸性球 5 五、腸道菌相 6 1. 腸道菌相與免疫系統 6 2. 腸道菌相與靈芝多醣 7 3. 腸道菌相與過敏型氣喘 8 第二章 研究動機 9 第三章 材料與方法 10 1. 實驗菌株和動物 10 2. 台灣紫芝培養基配製 10 2.1. 菌株保存用培養基 (PDA 培養基) 10 2.3. 醱酵槽培養基 (ME-YE培養基) 10 3. 台灣紫芝培養方法 11 3.1. 種菌培養 11 3.2. 搖瓶培養 11 3.3. 醱酵槽培養 11 4. PS-F2多醣體之回收及純化 11 5. 測定多醣體含量 12 6. 台灣紫芝多醣體對於小鼠過敏型氣喘之影響 12 6.1. 去除OVA抗原之內毒素 12 6.2. 口服PS-F2 12 6.3. Mouse immunization model for low dose (125 mg/kg) 13 6.4. Mouse immunization model for high dose (250 mg/kg) 13 6.5. OVA抗原致敏化 (immunization) 及鼻腔刺激 (challenge) 14 6.6. 呼吸道阻力測定 (airway hypersensitive response, AHR) 14 6.7. 支氣管肺泡灌洗 (bronchoalveolar lavage) 及BALF (bronchoalveolar lavage fluid) 製備 14 6.8. BALF細胞分析 15 6.9. OVA專一性抗體分析 16 6.10. 第二型免疫反應相關cytokine分析 16 7. 台灣紫芝多醣體對於腸道菌相之影響 17 7.1. 實驗架構 17 7.2. 糞便DNA抽取 17 7.3. 16S rDNA V3 V4 region PCR 19 7.4. DNA電泳及膠片純化 19 7.5. Index PCR 20 7.6. DNA Qubit定量 20 7.7. NGS MiSeq定序 21 7.8. 菌相分析 21 8. 統計與繪圖軟體之分析 21 第四章 實驗結果 22 一、口服PS-F2對於過敏型氣喘之影響 22 二、口服PS-F2對於腸道菌相之影響 25 第五章 討論 29 第六章 圖表 36 第七章 參考文獻 59 | |
dc.language.iso | zh-TW | |
dc.title | 台灣紫芝多醣體調節小鼠過敏型氣喘與腸道菌相之研究 | zh_TW |
dc.title | Regulation of mouse allergic asthma and gut microbiota by Ganoderma formosanum polysaccharides | en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李昆達(Kung-Ta Lee),江皓森(Hao-Sen Chiang) | |
dc.subject.keyword | 台灣紫芝,多醣體,過敏型氣喘,嗜酸性球,腸道菌相, | zh_TW |
dc.subject.keyword | Ganoderma formosanum,polysaccharide,allergic asthma,eosinophil,gut microbiota, | en |
dc.relation.page | 69 | |
dc.identifier.doi | 10.6342/NTU202004211 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-09-18 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1609202012081000.pdf 目前未授權公開取用 | 6.18 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。